Atlas›Domain VII · Transpersonal, psychedelic & altered states›Guide 037
Guide VII-037

Hypnodelic therapy (historical)

Jerome Levine, Arnold M. Ludwig1963Lexington, Kentucky
A 16 · L 59 · M 2519 interventions in the Trinity explorer14 described for recognition only
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the Levine & Ludwig "hypnodelic treatment technique" as described in their own reports. This covers the Lexington, Kentucky narcotic-addiction version (Levine, Ludwig & Lyle 1963; Levine & Ludwig 1965; the symposium paper "The Hypnodelic Treatment Technique") and the Mendota State Hospital, Wisconsin, alcoholism version (Ludwig, "Outline of Hypnodelic Therapy"; Ludwig, "LSD Treatment in Alcoholism"; Ludwig et al. 1969). Where the two versions differ, the guide says so.

HISTORICAL. NOT FOR USE. Hypnodelic therapy combined LSD, hypnosis and directive psychotherapy in a single session. LSD has been a Schedule I controlled substance in the US since 1970, and no regulated programme today offers this method. This entry is history only. It gives no doses, routes or administration details. Sections 4 and 5 describe what was done so that clinicians can recognise it, and then say what a clinician does with this knowledge now. [source: Bonson 2017; Levine & Ludwig, Hypnodelic Treatment Technique]

Source notes: what the three MAPS copies show of their publication details (partial, see Sources); the author list and publisher of the 1970 book, from Ludwig's own reference list and Krebs & Johansen 2012; the citation of the controlled five-technique comparison, corrected to 1965, American Journal of Psychotherapy 19:417; Ludwig's own statement on suggestibility and outcome (Section 4, A2); and the 2026 status of the LSD developer formerly called MindMed. The contents of the 1965 comparison paper, the 1967 chapter and the 1970 book are reported here only as later papers summarise them [uncertain]. Not verified [uncertain]: LSD's UK and UN legal status, the venues of Ludwig's Outline and LSD Treatment in Alcoholism, and the result of the second Phase 3 anxiety trial.

What it was. Jerome Levine and Arnold M. Ludwig were psychiatrists at the US Public Health Service Hospital in Lexington, Kentucky. In the early-to-mid 1960s they developed the method for hospitalised narcotic addicts. Ludwig later tested it with alcoholic men at Mendota State Hospital, Madison, Wisconsin. The name blends "hypnotic" and "psychedelic". The 1963 first report did not yet use the term. [source: Levine, Ludwig & Lyle 1963; Ludwig, Outline; Godvliet (student review)]

Core idea of change (as the authors stated it). Levine and Ludwig held that LSD's perceptual effects had little therapeutic value on their own. In their view, the unstructured drug experience had to be controlled and directed toward insight-oriented psychotherapy, and hypnosis was the tool for this. They argued that hypnosis made relaxation and a close working alliance possible, made the session easier to structure through its demand characteristics, allowed contradictory feelings and non-logical thinking to be explored, and eased links to the past. They argued that LSD lent old ideas new meaning and made the therapist's interpretations feel more significant. They stated that the method rested on rational psychological mechanisms, not mystical ones. They held that the particular theory of interpretation mattered less than giving the patient a coherent framework for understanding his or her problems. They offered as a hypothesis, not a finding, that the degree of altered consciousness might be causally linked to change. [source: Levine & Ludwig, Hypnodelic Treatment Technique]

What happened to it. The Lexington controlled comparison reported that the hypnodelic condition did best at short follow-up. The larger Mendota alcoholism trial found no LSD condition better than a no-therapy milieu control. Ludwig called these results "quite discouraging" and concluded that the apparent benefit was illusory. Tightening US drug regulation (1962–1970) then ended this line of research. [source: Ludwig, LSD Treatment in Alcoholism; Ludwig et al. 1969 abstract; Bonson 2017] A 2012 meta-analysis pooled the Mendota trial with five other 1960s randomised LSD-for-alcoholism trials and read the wider evidence more positively at early follow-up. It pooled all LSD arms together, so it did not test the hypnodelic component on its own. [source: Krebs & Johansen 2012]

2. Framework

Historical description. Not a protocol for use.

Format. The core was a single, intensive, individual treatment session with one therapist, embedded in an inpatient stay. There were no scheduled sessions afterwards. [source: Levine & Ludwig, Hypnodelic Treatment Technique]

Phases as published:

  1. Selection and screening. Lexington: inpatients recovering from narcotic addiction who had been recommended for psychotherapy at a staff conference and who volunteered. They were adults, free of serious physical illness, literate, with limited prior admissions, and they had passed brief suggestibility screens. Ludwig's Outline: no serious physical illness, no overt psychosis, no more than minimal organic brain damage, enough concentration to take part, and voluntary consent. Mendota: committed adult men with long alcoholism histories and limited prior admissions; the summary opened does not state exclusion criteria. [source: Levine & Ludwig 1965; Ludwig, Outline; Ludwig, LSD Treatment in Alcoholism]
  2. Preparatory session. Goal: a dynamic formulation of the patient's main problems, conflicts and habitual defences, and (Lexington) training in hypnosis. It consisted of a psychiatric history interview and, at Lexington, hypnotic training. The interval before treatment varied by report: a few days in 1963 and within about ten days in 1965 and in the symposium paper. Ludwig's Outline describes no separate hypnotic training session. [source: Levine, Ludwig & Lyle 1963; Levine & Ludwig 1965; Ludwig, Outline; Grof 1970]
  3. Treatment session: induction phase. Goal: a hypnotic trance and the drug state developing together. It was held in an ordinary office, with no special lighting or music. [source: Levine & Ludwig, Hypnodelic Treatment Technique]
  4. Treatment session: intensive therapy phase. Goal: directive, insight-interpretive work on the problems identified at the interview, including emotional re-experiencing (abreaction) and direct interpretation. It lasted roughly two to three hours. [source: Ludwig, Outline; Levine & Ludwig, Hypnodelic Treatment Technique]
  5. Closing. The therapist summarised, offered an explanation of symptoms, and gave post-hypnotic suggestions to recall the session and keep working on problems. [source: Ludwig, Outline; Grof 1970]
  6. Post-session phase. The patient spent the rest of the day alone in a private room on a medical ward, reflecting on problems. Nursing staff observed and offered support. Medical staff managed sleep disturbance that night, and a therapist visited the next morning before the patient returned to routine hospital life. [source: Levine & Ludwig, Hypnodelic Treatment Technique; Ludwig, Outline]
  7. Follow-up. This was research assessment only. Lexington assessed at two weeks and two months. Mendota assessed at 3, 6, 9, 12 and 18 months after release, using questionnaires, drinking reports, breath tests and interviews with relatives. Therapists were available on request, but no further therapy was scheduled. [source: Levine & Ludwig, Hypnodelic Treatment Technique; Ludwig, LSD Treatment in Alcoholism]

Criteria for moving between phases. The sources describe a fixed sequence driven by the session timetable, not clinical criteria. The one explicit criterion was passing suggestibility screens before entry (Lexington). [source: Levine & Ludwig 1965] Criteria for ending the session early, or for medical escalation beyond ward transfer, are not described in the sources. [uncertain]

Comparison conditions used in the research (useful for reading the literature):

  • Lexington, five single-session arms: hypnodelic (LSD + hypnosis + psychotherapy); psychedelic (LSD + the same psychotherapy, no hypnosis); "delic" (LSD alone, with the patient told to work on problems independently and the experimenter present but mostly silent); hypnotherapy (hypnosis + psychotherapy, no drug); and psychotherapy alone. [source: Levine & Ludwig 1965]
  • Mendota, four arms: hypnodelic; psychedelic; LSD with a therapist who intervened only for panic or anxiety; and a no-therapy milieu control, in which patients spent equivalent time writing autobiographies of their problems and future plans. Half of each arm was also randomised to a disulfiram (Antabuse) programme after discharge. All arms received the hospital's milieu programme. [source: Ludwig, LSD Treatment in Alcoholism; Ludwig et al. 1969 abstract]

Legal and regulatory status (as of the sources' dates). In the US, the 1962 Kefauver-Harris Amendments introduced safety and efficacy requirements for drug research [source: Bonson et al. 2018, abstract]; the dates of the later consent and IRB requirements are [uncertain: secondary, unverified]. Sandoz stopped supplying psychedelics for research in 1965, and nonmedical use was banned in 1970, when LSD was placed in Schedule I of the Controlled Substances Act [source: Hall 2021]. LSD is still Schedule I in the US. MindMed's pharmaceutical LSD product MM120 received FDA Breakthrough Therapy designation for generalised anxiety disorder in March 2024 and entered Phase 3 trials, in a monitored "drug-only" model with no psychotherapy and no hypnosis. [source: Drug Discovery & Development, Oct 2024] By 2026 the company had rebranded as Definium Therapeutics (Nasdaq: DFTX) and the product as DT120. In August 2026 the company reported that its Phase 3 depression trial (Emerge) met its primary and all key secondary endpoints. Its first Phase 3 anxiety trial (Voyage) was reported on 14 August 2026 to have met its primary endpoint. The second anxiety trial (Panorama) was due to report in September 2026; its result is [uncertain]. No FDA submission date had been announced by mid-August 2026, so no LSD medicine was approved at that point. The company's own risk statement says that products containing Schedule I substances would need DEA rescheduling before they could be marketed in the US. The 2026 materials cited do not mention psychotherapy or hypnosis. [source: Definium Q2 2026 release, 6 Aug 2026; GeneOnline, 14 Aug 2026] LSD is understood to be in Schedule I of the UN 1971 Convention on Psychotropic Substances and in Class A / Schedule 1 under UK law [uncertain: secondary, unverified]. Hypnosis on its own is legal. Who may practise it is regulated differently in different places. [synthesis]

3. Guiding principles

Part A gives the principles Levine and Ludwig stated, with what each meant in practice then. Part B gives the principles for a clinician today who meets this history.

A. Historical principles (as published)

  • The drug experience must be structured, not left to unfold. In practice the therapist shaped the session toward emotional conflict areas and away from visual imagery. [source: Levine, Ludwig & Lyle 1963]
  • Hypnosis is the instrument of control. In practice trance was induced and kept up throughout, and trance lightening was countered by repeated suggestion. [source: Ludwig, Outline; Grof 1970]
  • Therapy is directive. In practice Ludwig describes the therapist as more directive than in ordinary psychotherapy, steering attention to key problems. [source: Ludwig, Outline]
  • Focus on pre-identified problems. In practice the session's content was set by the preparatory interview's formulation of conflicts and defences. [source: Ludwig, Outline; Levine & Ludwig, Hypnodelic Treatment Technique]
  • Insight plus emotional re-experiencing. In practice the therapist encouraged recall and abreaction and offered direct interpretations, close to Ellis's "insight-interpretive" approach. [source: Levine & Ludwig 1965; Hypnodelic Treatment Technique]
  • A coherent explanation matters more than a particular theory. In practice the closing gave the patient a plausible account of symptoms. [source: Ludwig, Outline; Hypnodelic Treatment Technique]
  • Rational, not mystical, mechanisms. In practice mystical or transcendent content was not sought. [source: Hypnodelic Treatment Technique]
  • Carry-over through post-hypnotic suggestion. In practice patients were told to remember the session and keep working on their problems afterwards. [source: Levine, Ludwig & Lyle 1963; Grof 1970]
  • No efficacy claims without controlled follow-up. In practice the authors withheld conclusions until controlled data existed, and Ludwig accepted the negative Mendota result. [source: Levine, Ludwig & Lyle 1963; Ludwig, LSD Treatment in Alcoholism]

B. Principles for today's clinician [synthesis unless tagged]

  • Not for use. Never combine hypnosis or any directive suggestion technique with a client's psychedelic use, whether in clinic, retreat or underground settings. Decline, and explain why.
  • Self-report is not behaviour change. Ludwig's own conclusion was that patients' reports diverged from what they actually did. [source: Ludwig, LSD Treatment in Alcoholism] Judge change by behaviour, not by how powerful the experience was.
  • Heightened suggestibility is a risk to consent. Lemercier & Terhune report that LSD appears to raise suggestibility. [source: Lemercier & Terhune 2018] In practice, interpretations given in an altered state carry undue weight, so avoid anything that resembles that.
  • Know the institutional history. Lexington was a combined prison and hospital. Separate research at its Addiction Research Center has been documented as coercive. [source: Strauss & Williams 2021 blog] In practice, ask former patients about their experience without assuming either harm or benefit.
  • Harm reduction and integration, not facilitation. For clients who use psychedelics outside regulated settings, the role is assessment, safety planning, general risk education, referral and drug-free integration.

4. Intervention inventory

How to read this section. Part A lists every component the sources describe, as historical record, NOT FOR USE. The "Steps" are given in general terms only, with no drug quantities, routes or timing of administration. The authors published no verbatim scripts, so none are given. "Example language" is written for the present-day clinician (for instance, explaining the history to a client or doing the legitimate drug-free counterpart), not for reproducing a drug session. Part B gives the procedures a clinician uses today with this knowledge. [synthesis for structure]

A. Historical components (Levine & Ludwig)

A1. Preparatory psychiatric interview and dynamic formulation

  • Purpose / when used: To identify the patient's main complaints, conflicts and habitual defences, which then set the agenda for the treatment session. It was used in every arm of the trials. [source: Levine & Ludwig 1965; Ludwig, Outline]
  • Steps (as described): (1) A long single interview, about 90 minutes at Lexington, covering presenting complaints, family and marital history, the patient's self-description and habitual defences. (2) The therapist chose the predominant issues to focus on. (3) In the research, baseline questionnaires followed. [source: Levine & Ludwig, Hypnodelic Treatment Technique; Levine & Ludwig 1965]
  • Example language (illustrative, present-day drug-free use): "Before we decide on a focus, I'd like to understand the patterns that keep recurring for you: in your family, your relationships, and how you protect yourself when things get hard."
  • Watch for: The formulation was the therapist's, built in one meeting and then pressed on the patient in a highly suggestible state. Today, a formulation is shared, revised with the client and never imposed. [synthesis]

A2. Suggestibility screening

  • Purpose / when used: Before entry (Lexington), to confirm that patients responded to basic suggestion. [source: Levine & Ludwig 1965; Levine, Ludwig & Lyle 1963]
  • Steps (as described): Standard brief suggestibility tests of the period, the hand-clasp and postural-sway tests. Only patients who responded were taken into the study. [source: Levine & Ludwig 1965]
  • Example language (illustrative, present-day clinical hypnosis): "This short exercise just shows us how your body responds to imagination. There's no right or wrong result, and you can open your eyes and stop at any point."
  • Watch for: For the authors' own data, Ludwig's Outline settles the question: there was "no significant correlation between the patient's degree of suggestibility and therapeutic results attained". He attributes this to "our research data" and does not say which study or patient group. The symposium paper does not relate suggestibility to outcome at all. [source: Ludwig, Outline; Hypnodelic Treatment Technique] Godvliet's student review agrees. The secondary remark that suggestibility "seemed to contribute" (Lemercier & Terhune) is not supported by the primary text opened. Screening for suggestibility also selected the people most open to the therapist's influence. [synthesis]

A3. Hypnotic training session (Lexington version)

  • Purpose / when used: To familiarise the patient with hypnosis, gauge responsiveness and make induction easier on the treatment day. Ludwig's later Outline (Mendota) omitted this separate session. [source: Levine & Ludwig, Hypnodelic Treatment Technique; Ludwig, Outline]
  • Steps (as described): (1) An eye-fixation induction with suggestions of drowsiness, tiredness and relaxation. (2) In the 1965 study, baseline questionnaires were given again under hypnosis. (3) The patient was then woken. [source: Levine & Ludwig 1965; Grof 1970]
  • Example language (illustrative, present-day drug-free hypnosis): "Today is only practice, so you know what hypnosis feels like. You'll stay aware of where you are, and you can come out of it whenever you choose."
  • Watch for: In 1965, consent was given without knowing which drug, if any, would be received. [source: Levine & Ludwig 1965] Consent of that kind falls short of current standards. [synthesis]

A4. Combined-state induction and deepening

  • Purpose / when used: The method's defining step: to have a hypnotic trance and the drug state develop together, so that the drug experience was "controlled" from the outset. [source: Levine & Ludwig, Hypnodelic Treatment Technique; Lemercier & Terhune 2018]
  • Steps (as described, general terms only): (1) A brief settling period. (2) An extended eye-fixation induction with relaxation and drowsiness suggestions, deepened as the drug's effects emerged. (3) Hypnotic "challenges" (tests of trance depth) were avoided. (4) In the 1965 study, deepening suggestions avoided the content of the outcome questionnaire. [source: Ludwig, Outline; Levine & Ludwig 1965]
  • Example language: None provided. This is a drug-session procedure and is not for use.
  • Watch for (historical): The authors reported that drug and trance effects blended fairly smoothly. [source: Grof 1970] Racing thoughts were noted early in sessions. [source: Ludwig, Outline]

A5. Directive insight-interpretive psychotherapy within the combined state

  • Purpose / when used: The active treatment: to work on the formulated problems while the patient was both hypnotised and drug-affected. [source: Levine & Ludwig, Hypnodelic Treatment Technique]
  • Steps (as described): (1) The therapist directed attention to the key problem areas from the interview. (2) The patient was encouraged to examine current difficulties in the light of early-life experiences, traumatic events and relationships with parents, siblings or spouse. (3) The therapist offered direct interpretations and dynamic formulations, in an orientation the authors likened to Ellis's insight-interpretive therapy. (4) Work continued for roughly two to three hours. [source: Levine, Ludwig & Lyle 1963; Ludwig, Outline; Levine & Ludwig 1965]
  • Example language: None for the drug session. In ordinary drug-free psychodynamic work, a present-day equivalent (illustrative) is: "I wonder whether the way you go quiet when your partner is angry connects with what you described about your father. Does that fit, or not quite?" Note the invitation to disagree, which the historical directive stance did not build in. [synthesis]
  • Watch for (historical): Patients attributed heightened significance to the therapist's interpretations. [source: Hypnodelic Treatment Technique] The authors saw this as a mechanism of change. Today it is better understood as a risk of undue influence. [synthesis]

A6. Encouraging recall and abreaction

  • Purpose / when used: Emotional re-experiencing of past events, which the authors linked to change. Ludwig presented the link as his "general impression", not a tested finding: the more intense the appropriate emotional experience (abreaction) during therapy, the more benefit patients reported afterwards. [source: Ludwig, Outline; Hypnodelic Treatment Technique] Godvliet's student review calls this a correlation with outcome, which overstates it. [source: Godvliet (student review)] The benefit was also self-reported, and at Mendota self-reports diverged from behaviour. [synthesis; Ludwig, LSD Treatment in Alcoholism]
  • Steps (as described): The therapist encouraged the patient to recall and emotionally relive significant past events within the session, then linked them to the formulation. [source: Ludwig, Outline; Grof 1970]
  • Example language: None provided (not for use).
  • Watch for: Drug-free, suggestion-heavy recall of trauma can distort memory and destabilise people without trauma-focused safety steps (stabilisation, titration, consent). [synthesis] One Lexington patient's psychopathology worsened three weeks after treatment. [source: Hypnodelic Treatment Technique]

A7. Redirection when drug phenomena are used defensively

  • Purpose / when used: When patients shifted attention to visual or perceptual effects as emotionally charged material approached. [source: Ludwig, Outline]
  • Steps (as described): The therapist named the shift as a defence (interpretation) and firmly redirected the patient to the problem area. [source: Ludwig, Outline]
  • Example language: None provided (not for use).
  • Watch for: This shows how strongly directive the method was: the patient's own way of regulating the experience was overridden. [synthesis]

A8. Trance maintenance and weak-trance workaround

  • Purpose / when used: To keep hypnotic structure over a long session. [source: Ludwig, Outline; Ludwig, LSD Treatment in Alcoholism]
  • Steps (as described): (1) When the trance lightened, relaxation and trance suggestions were repeated. (2) Hypnotic control was reinforced periodically by suggestion (Mendota). (3) When the trance was weak, therapists kept the patient's eyes closed and relied on the patient's role-taking and compliance to keep directing the session. [source: Ludwig, Outline; Ludwig, LSD Treatment in Alcoholism]
  • Example language: None provided (not for use).
  • Watch for: The reliance on compliance is an admission that "hypnosis" could become social pressure. [synthesis]

A9. Closing summary and "plausible explanation"

  • Purpose / when used: At the end of active therapy, to give the patient a coherent framework. The authors regarded such a framework as more important than any specific theory. [source: Ludwig, Outline; Hypnodelic Treatment Technique]
  • Steps (as described): The therapist summarised the material that had emerged and offered a plausible explanation of the patient's symptoms. [source: Ludwig, Outline]
  • Example language (illustrative, present-day drug-free session ending): "Let's pull together what came up today. Here's how I'm understanding it so far. Tell me what fits and what doesn't, and we'll keep revising it."
  • Watch for: A "plausible" explanation given in an altered, suggestible state can be adopted as truth without scrutiny. [synthesis]

A10. Post-hypnotic suggestions for carry-over

  • Purpose / when used: To extend the session's effect. [source: Levine, Ludwig & Lyle 1963; Grof 1970]
  • Steps (as described): Before waking, the patient was told to remember the session's details and keep working on, and thinking about, the problems discussed. When challenged at the symposium, Levine said the suggestions were limited to this and were not meant to prolong drug effects. [source: Hypnodelic Treatment Technique (discussion)]
  • Example language (illustrative, present-day drug-free hypnosis): "As you come back to full alertness, you can keep whatever was useful from today and leave the rest. Notice what stays with you this week and bring it next time."
  • Watch for: Symposium discussants raised the question of whether outcomes reflected suggestion and expectation rather than the treatment. [source: Hypnodelic Treatment Technique (discussion)]

A11. Post-session solitary reflection with nursing observation

  • Purpose / when used: For the rest of the treatment day, to let the patient keep reflecting while staff ensured safety. [source: Hypnodelic Treatment Technique; Ludwig, Outline]
  • Steps (as described): (1) The patient was woken and taken to a private room on a medical ward. (2) The patient was left largely alone to reflect. (3) A nurse observed frequently, checked vital signs and offered support (a medical-staff responsibility). (4) Sleep disturbance that night was managed medically. (5) A therapist visited the next morning, and the patient then returned to the routine ward programme. [source: Hypnodelic Treatment Technique; Ludwig, Outline]
  • Example language: None provided (not for use).
  • Watch for (historical): Insomnia was the most common side effect. Isolated cases of transient anxiety, agitation, depression, headache, nausea and dizziness occurred; one paranoid reaction resolved within 72 hours; and one patient deteriorated after three weeks and needed a more closely supervised ward. [source: Hypnodelic Treatment Technique]

A12. Follow-up and on-demand availability

  • Purpose / when used: Outcome assessment (Lexington at two weeks and two months; Mendota up to 18 months), with therapists available if patients asked. [source: Hypnodelic Treatment Technique; Ludwig, LSD Treatment in Alcoholism]
  • Steps (as described): Scheduled research assessments; no scheduled further therapy. [source: Hypnodelic Treatment Technique]
  • Watch for: Discussants criticised the short follow-up and the absence of post-session therapy. [source: Hypnodelic Treatment Technique (discussion)] Modern psychedelic-assisted protocols build in integration sessions, and this method lacked them. [synthesis]

A13. Control and comparison procedures (research only)

  • Purpose: To isolate the contributions of drug, hypnosis and psychotherapy. [source: Levine & Ludwig 1965; Ludwig, LSD Treatment in Alcoholism]
  • Steps (as described): "Delic" (LSD alone): the patient worked on problems independently, with paper and pencil available, and the experimenter stayed in the room but said little; at Mendota the therapist intervened only for panic or anxiety. Milieu control: the patient spent equivalent time writing an autobiography of problems and future plans. [source: Levine & Ludwig 1965; Ludwig, LSD Treatment in Alcoholism]
  • Watch for: The autobiography control did as well as every LSD arm at Mendota, which is the key point when assessing claims for the method. [source: Ludwig, LSD Treatment in Alcoholism]

B. What a clinician does with this knowledge today

B1. Appraising historical claims

  • Purpose / when used: When a client, colleague, course or website cites hypnodelic or 1960s LSD therapy as proof that a hypnosis-plus-psychedelic approach works. [synthesis]
  • Steps: (1) Separate the two programmes. At Lexington, with about 70 patients and single sessions, the hypnodelic group improved most at two weeks and two months, but the outcomes were self-reported. At Mendota, with 176 men followed up to 18 months, no LSD arm did better than writing an autobiography in the milieu programme. [source: Hypnodelic Treatment Technique; Ludwig, LSD Treatment in Alcoholism] (2) Note that the 1965 Psychopharmacologia paper measured how altered consciousness was, not clinical outcome. [source: Levine & Ludwig 1965] (3) Note the authors' own caution, and Ludwig's verdict that the apparent benefit was illusory. (4) Note Bonson's assessment that most 1960s LSD studies were small, loosely controlled and incompletely reported. [source: Bonson 2017] (5) Correct a secondary claim: a student review states the original studies had no control groups, but both trials did. [source: Godvliet; Levine & Ludwig 1965] (6) If someone cites the 2012 meta-analysis, note what it did. It pooled the Mendota trial (132 LSD, 44 control) with five other 1960s trials and found a pooled benefit at first follow-up that was no longer significant at the longest follow-up. It rated Mendota at high risk of bias for blinding, because concealment ended at the drug session, and for selective outcome reporting. It combined all LSD arms, so it says nothing specific about adding hypnosis. [source: Krebs & Johansen 2012]
  • Example language (illustrative): "The strongest test of this method, the larger and longer study, found that patients did just as well writing an autobiography as with any of the LSD treatments. The researcher himself called the earlier impression illusory."
  • Watch for: Marketing that cites only the Lexington pilot or two-month data. [synthesis]

B2. Responding to a request for hypnosis during or around psychedelic use

  • Purpose / when used: When a client asks you to hypnotise or "guide" them during a psychedelic experience, or to reproduce the hypnodelic method. [synthesis]
  • Steps: (1) Decline clearly. (2) Explain the reasons: legal status, the absence of a regulated protocol, the documented rise in suggestibility, and the negative controlled trial. (3) Explore what the client hopes for, such as insight, relief or meaning. (4) Offer legitimate routes: evidence-based therapy, drug-free hypnosis for indicated problems, or referral to a regulated clinical trial where one exists. [synthesis; Lemercier & Terhune 2018 for suggestibility]
  • Example language (illustrative): "I won't do hypnosis alongside a psychedelic. It isn't legal or regulated, and suggestion carries much more weight in that state than either of us can control. What were you hoping it would give you? Let's look at safer ways to work toward that."
  • Watch for: The client hearing the refusal as disapproval of them; this is covered in Section 5. [synthesis]

B3. Harm-reduction assessment for clients using psychedelics outside regulated settings

  • Purpose / when used: When a client discloses current or planned use. [synthesis]
  • Steps: (1) Take a full history, including psychiatric history (personal or family history of psychosis or bipolar disorder), cardiovascular and other medical history, current medications, and substance use. (2) Educate in general terms about psychological risks and about interactions with prescribed medicines, without dosing, and refer medication questions to the prescriber. (3) Make a safety plan: who is present, an exit plan, and crisis contacts. (4) Name the specific risk of letting a facilitator use hypnosis or heavy suggestion during the experience. (5) Refer to a medical practitioner where risk is present. [synthesis]
  • Example language (illustrative): "I'm not going to help you plan the use itself, but I do want you safe. Can we go through your health history and who'll be with you, and talk about what to do if it goes badly?"
  • Watch for: Disclosures of facilitators who promise "guided" or "hypnotic" journeys, touch, or recovered memories. [synthesis]

B4. Integration support after a psychedelic experience (drug-free)

  • Purpose / when used: When a client brings confusing, distressing or seemingly revelatory material from a past experience. [synthesis]
  • Steps: (1) Help the client describe the experience in their own words, before you offer any frame. (2) Treat insights as hypotheses to test against daily life, which mirrors Ludwig's finding that self-report and behaviour diverged. [source: Ludwig, LSD Treatment in Alcoholism] (3) Distinguish content the client generated from content a guide or facilitator suggested. (4) Use ordinary evidence-based methods for any resulting anxiety, depersonalisation or intrusive memories. [synthesis]
  • Example language (illustrative): "Which parts of that came from you, and which came from what the guide said to you? Let's see what this insight looks like when you try it out this week."
  • Watch for: Fixed beliefs adopted during the experience, especially about family or abuse, that were suggested by a guide. [synthesis]

B5. Drug-free hypnosis in relation to psychedelic experiences (proposed, unvalidated)

  • Purpose: Lemercier & Terhune proposed that hypnosis might be used for preparation, for managing difficult experiences, or for integration through post-hypnotic suggestion, and to re-evoke states without drugs. They describe these as proposals needing formal development, not established practice. [source: Lemercier & Terhune 2018] [uncertain]
  • Steps: Use only within a regulated research protocol. In ordinary practice, use clinical hypnosis only for its established indications, by a trained practitioner, with standard consent. [synthesis]
  • Watch for: Workshops that sell "hypnodelic" or "psychedelic hypnosis" as a proven method. [synthesis]

B6. Supporting people who took part in historical psychedelic research or were affected by it

  • Purpose / when used: When an older client (or their family) describes taking part in 1950s–70s drug research, including research at Lexington. [synthesis]
  • Steps: (1) Listen without assuming either harm or benefit. (2) Ask about consent: did they know what they were given? Lexington hypnodelic participants were not told which drug, if any, they would receive. [source: Levine & Ludwig 1965] (3) Be aware that separate research at Lexington's Addiction Research Center has been documented as coercive, with prisoner-patients paid in drugs and some kept in studies after asking to leave. Strauss and colleagues report that this harmed Black participants disproportionately and has left lasting mistrust. [source: Strauss & Williams 2021 blog] (4) Address the client's mistrust of clinicians and researchers directly. (5) Assess for trauma symptoms and offer evidence-based treatment. (6) Signpost to records requests or legal advice if the client wants them. [synthesis]
  • Example language (illustrative): "It makes sense to be wary of doctors after being given something you didn't agree to. We'll go at your pace, and you decide what we focus on."
  • Watch for: Shame, distrust and reluctance to take prescribed medication. [synthesis]

5. Handling problems

A. Problems the authors reported, and how they responded (historical, not for use)

  • Weak or absent trance. The therapist kept the patient's eyes closed and continued directing the session through the patient's role-taking and compliance. [source: Ludwig, Outline] Today's reading: this is pressure, not hypnosis, and a reason the method should not be revived. [synthesis]
  • Trance lightening during the session. Relaxation and trance suggestions were repeated, and control was reinforced periodically. [source: Ludwig, Outline; Ludwig, LSD Treatment in Alcoholism]
  • Retreat into perceptual effects ("drug symptoms as defence"). The therapist interpreted the shift and firmly redirected the patient to the problem. [source: Ludwig, Outline]
  • Therapist fatigue. Ludwig found the sessions very demanding. The sources propose no remedy. [source: Ludwig, Outline]
  • Adverse effects. Insomnia was common. Transient anxiety, agitation, depression and somatic complaints occurred, and there was one transient paranoid reaction. The response was ward observation, medical management of sleep, and transfer to a closer-supervised ward for one patient who deteriorated after three weeks. [source: Hypnodelic Treatment Technique] Systematic adverse-event methods are not described. [uncertain]
  • Non-response at follow-up (Mendota). Most patients had returned to drinking by 6 to 12 months, whatever the arm. Ludwig responded by reporting the null result and abandoning his claims for LSD in alcoholism. [source: Ludwig, LSD Treatment in Alcoholism]

B. Problems a clinician meets today [all synthesis unless tagged]

  • A client insists the method is proven and wants it. Go through B1: the two studies, the null Mendota result and Ludwig's own verdict. Validate the wish for a powerful single intervention, then plan a realistic course of evidence-based therapy.
  • Rupture after you decline to take part in psychedelic use. Name the rupture. Separate the boundary ("I won't combine therapy or hypnosis with drug use") from your regard for the client. Restate what you will do: harm reduction, integration and continuing therapy. Invite their reaction and repair before moving on.
  • A client was hypnotised or heavily guided by a facilitator during use and now holds new beliefs, for example about childhood abuse. Do not confirm or dismiss the beliefs. Explore where each belief came from and how it was suggested. Explain in general terms that suggestibility can be heightened in such states. [source: Lemercier & Terhune 2018] Hold the beliefs as uncertain, attend to the distress, and avoid further memory-recovery techniques. Consider consultation, and safeguarding if current risk to others is disclosed.
  • Overwhelm or destabilisation after an experience (anxiety, depersonalisation, intrusive images, suicidal thoughts). Assess risk using standard practice, stabilise with grounding and sleep and routine, and treat with evidence-based methods. Refer for medical or psychiatric assessment if there are psychotic or manic features, or a family history of them. For suicide risk, follow standard risk assessment and safety planning, including lethal-means counselling limited to storage and removal.
  • A client is still using and does not follow the safety plan. Keep the alliance, revisit the plan without moralising, use motivational interviewing to explore ambivalence, and document education and referrals given.
  • A colleague or service advertises "hypnodelic" or "psychedelic hypnotherapy". Check for these red flags: hypnosis or suggestion delivered while clients are drug-affected; recovered-memory claims; a single "breakthrough" session with no integration; consent obtained without disclosure; and promotion based only on the 1960s Lexington data. Raise concerns with the colleague, then follow your professional body's reporting procedures. Where illegal supply is involved, take advice on your legal and professional duties in your jurisdiction.
  • A former research participant is stuck in distrust of clinicians. Work from B6. Give transparent explanations, offer choice at every step, put consent in writing for any new intervention, and accept a slower pace.
  • Stuck or ambivalent clients who idealise a single transformative session. Note that Ludwig found that self-reports of change diverged from actual behaviour. [source: Ludwig, LSD Treatment in Alcoholism] Shift the focus to small behavioural experiments and measurable goals.

Sources

Consulted:

Cited via other sources [uncertain on content]:

  • Ludwig, A. M., Levine, J., & Stark, L. H. (1970). LSD and Alcoholism: A Clinical Study of Treatment Efficacy. Springfield, IL: Charles C Thomas. The author list and publisher are confirmed by Ludwig's own reference list (where the book is "in press") and by Krebs & Johansen 2012, which cites it as a report of the Mendota trial. Its contents are reported here only through Ludwig's papers and Krebs & Johansen 2012. [uncertain]
  • Ludwig, A. M., & Levine, J. (1965). A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. American Journal of Psychotherapy, 19, 417 ff. Correction: an earlier version of this guide dated it 1967 with volume 21. Ludwig's Outline cites it as 1965, vol. 19, p. 417. This is the Lexington controlled outcome report. Its outcomes are reported here as the symposium paper summarises them. [uncertain]
  • Ludwig, A. M., & Levine, J. (1967). Hypnodelic therapy. In J. Masserman (Ed.), Current Psychiatric Therapies, Vol. 7. New York: Grune & Stratton. Cited in Ludwig, LSD Treatment in Alcoholism; its content is not used here.
  • Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2021/22). Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal of Medical Ethics. Cited through the blog summary.
← Previous · VII-036Anaclitic LSD therapy (historical)Next · VII-038 →Naranjo's MDA, harmaline and ibogaine therapy (historical)